Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2006-03-20
2010-11-23
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C435S377000
Reexamination Certificate
active
07837990
ABSTRACT:
This invention relates to the in vivo expansion of NKT cells by their exposure to mature dendritic cells expressing α-galactosyl ceramide and to methods of use thereof in modulating immune responses, such as anti-cancer responses, and enhancing memory responses.
REFERENCES:
patent: 5405772 (1995-04-01), Ponting
patent: 2002/0164331 (2002-11-01), Exley et al.
patent: 2003/0157135 (2003-08-01), Tsuji et al.
patent: WO 93/20185 (1993-10-01), None
patent: WO 95/00632 (1995-01-01), None
patent: WO 95/06112 (1995-03-01), None
Mortreux et al, Leukemia, 2003, vol. 17, , pp. 26-38.
Bender, A. et al. “Improved Methods for the Generations of Dendritic Cells from NonProliferating Progenitors in Human Blood,”J. Immunol. Methods196 121-135 (1996).
O'Doherty, U. et al., “Dendritic Cells Freshly Isolated from Human Blood Express CD4 and Mature into Typical Immunostimulatory Dendritic Cells After Culture in Monocyte-Conditioned Medium,”J. Exp. Med. 178: 1067-1078 (1993).
Bonifaz, L. et al., “Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+T Cell Tolerance,”J. Exp. Med. 196(12) 1627-1638 (2002).
Manavalan, J.S., et al. “High Expression of ILT3 and ILT4 is a General Feature of Tolerogenic Dendritic Cells,”Transpl. Immunol. 11: 245-258 (2003).
Romani, N. et al., “Proliferating Dendritic Cell Progenitors in Human Blood,”J. Exp. Med. 180: 83-93 (1994).
O'Doherty, U. et al. “Human Blood Contains Two Subsets of Dendritic Cells, One Immunologically Mature and the Other Immature,”Immunology82 487-493, (1994).
Steinman, R. M., et al., “Tolerogenic Dendritic Cells”Annu. Rev. Immunol. 21, 685-711, (2003).
Banchereau, J., et al., “Immunobiology of Dendritic Cells,”Annu. Rev. Immunol., 18,767-811, (2000).
Mellman, I. et al., “Dendritic Cells: Specialized and Regulated Antigen Processing Machines,”Cell106, 255-258 (2001).
Steinman, R. M. et al., “Avoiding Horror Autotoxicus: The Importance of Dendritic Cell in Peripheral T Cell Tolerance,”Cell Proc. Natl. Acad. Sci. USA99, 351-358, (2002).
Brimnes, M. K., et al., “Influenza Virus-Induced Dendritic Cell Maturation is Associated with the Induction of Strong T Cell Immunity to a Coadministered, Normally Nonimmunogenic Protein,”J. Exp. Med. 198,133-144, (2003).
Regnault, A. et al. “FCγ Receptor-Mediated Induction of Dendritic Cell Maturation and major Histocompatibility Complex Class I-Restricted Antigen Presentation After Immune Complex Internalization,”J. Exp. Med. 189, 371-380 (1991).
Ravetch, J. V. et al., “IgG Fc Receptors”,Annu. Rev. Immunol., 19, 275-290, (2001).
Bolland, S. et al. “Genetic Modifiers of Systemic Lupus Erythematosus in FcγRIIB-/-Mice,”J. Exp. Med. 195, 1167-1174 (2002).
Bolland, S. et al. “Spontaneous Autoimmune Disease in FcγRIIB-Deficient Mice Results from Strain-Specific Epistasis”,Immunity13, 277-285 (2000).
Clynes, R. A. et al. “Inhibitory Fc Receptors Moduclate in vivo Cytoxicity Against Tumor Targets”,Nat. Med. 6(4), 443-446 (2000).
Bolland,S. et al., “SHIP Modulates Immune Receptor Responses by Regulating Membrane Association of Btk”,Immunity8, 509-516, (1998).
Bolland, S. et al., “Inhibitory Pathways Triggered by ITIM-Containing Receptors,”Adv. Immunol., 72, 149-177, (1999).
Amigorena, S. “Feγ Receptors and Cross-Presentation in Dendritic Cells,”J. Exp. Med. 195, F1-F3, (2002).
Dhodapkar, K. et al. “Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-Specific Killer T Cells by Dendritic Cells,”J. Exp. Med. 195,125-133 (2002).
Selenko, N. et al. “Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies?”J. Clin. Immunol. 22, 124-130, (2002).
Kita, H. et al. “Identification of HLA-A2-Restricted CD8+ Cytotoxic T Cell Responses in Primary Biliary Cirrhosis: T Cell Activation is Augmented by Immune Complexes Cross-Presented by Dendritic Cells,”J. Exp. Med. 195,113-123, (2002).
Nagata, Y. et al. “Differential Presentation of a Soluble Exogenous Tumor Antigen, NY-ESO-1, by Distinct Human Dendritic Cell Populations,”Proc. Natl. Acad. Sci. USA 99, 10629-10634, (2002).
Dhodapkar, M. V. et al. “T Cells from the Tumor Microenvironment of Patients with Progressive Myeloma can Generate Strong, Tumor-Specific Cytolytic Responses to Autologous, Tumor-loaded Dendritic Cells,”Proc. Natl. Acad. Sci. 99,13009-13013, (2002).
Rafiq, K. et al. “Immune Complex-Mediated Antigen Presentation Induces Tumor Immunity,”J. Clin. Invest. 110, 71-79, (2002).
Gil-Torregrosa, B. C. et al., “Control of Cross-Presentation During Dendritic Cell Maturation,”Eur. J. Immunol. 34,398-407, (2004).
Rodriguez, A. et al., “Selective Transport of Internalized Antigens to the Cytosol for MHC Class I Presentation in Dendritic Cells”,Nat. Cell Biol. 1, 362-368, (1999).
Sedlik, C. et al., “A Critical Role for Syk Protein Tyrosine Kinase in Fc Receptor-Mediated Antigen Presentation and Induction of Dendritic Cell Maturation,”J. Immunol. 170, 846-852, (2003).
Akiyama, K. et al. “Targeting Apoptotic Tumor Cells to FcγR Provides Efficient and Versatile Vaccination Against Tumors by Dendritic Cells,”J. Immunol. 170,1641-1648, (2003).
Ravetch, J. V. “A Full Complement of Receptors in Immune Complex Diseases,”J. Clin. Invest. 110, 1759-1761, (2002).
Kalergis, A. M. et al. “Inducing Tumor Immunity Through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells,”J. Exp. Med. 195, 1653-1659, (2002).
Jonuleit, H. et al., “Pro-inflammatory Cytokines and Prostaglandins Induce Maturation of Potent Immunostimulatory Dendritic Cells Under Fetal Calk Serum-Free Conditions,”Eur. J. Immunol. 27, 3135-3142, (1997).
Sallusto, F., et al., “Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells is Maintained by Granulocyte/Macrophage Colony-Stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor,”J. Exp. Med. 179,1109-1118, (1994).
Bave, U., et al., “FcγRIIa is Expressed on Natural IFN-α-Producing Cells (Plasmacytoid Dendritic Cells) and is Required for the IFN-α Production Induced by Apoptotic Cells Combined with Lupus IgG,”J. Immunol. 171, 3296-3302, (2003).
Schifferli, J. A. et al., “Physiological and Pathological Aspects of Circulating Immune Complexes,”Kidney Int. 35, 993-1003, (1989).
Mustafa, A.S., et al., “BCG Induced CD4+Cytotoxic T Cells From BCG Vaccinated Healthy Subjects: Relation Between Cytotoxicity and Suppression In Vitro,”Clin. Exp. Immunol., 69, 255-262, (1987).
Kaliński, P., et al. “Prostaglandin E2is a Selective Inducer of Interleukin-12 p40 (IL-12p40) Production and an Inhibitor of Bioactive IL-12p70 heterodimer,”Blood, 97, 3466-3469, (2001).
Heath, W. R. et al., “Cross-Presentation, Dendritic Cells, Tolerance and Immunity”,Annu. Rev. Immunol. 19, 47-64, (2001).
Wardemann, H., et al., “Predominant Autoantibody Production by Early Human B Cell Precursors,”Science, 301,1374-1377, (2003).
Li, X., et al. “A Novel Polymorphism in the Fcγ Receptor IIB (CD32B) Transmembrane Region Alters Receptor Signaling,”Arthritis Rheum. 48, 3242-3252, (2003).
Su, K. et al., “A Promoter Haplotype of the Immunoreceptor Tyrosine-Based Inhibitory Motif-Bearing FcγRIIb Alters Receptor Expression and Associates with Autoimmunity. I. Regulatory FCGR2B Polymorphisms and Their Association with Systemic Lupus Erythematosus,”J. Immunol. 172, 7186-7191, (2004).
Fukuy
Dhodapkar Madhav V
Steinman Ralph M.
Canella Karen A
Fox Rothschild LLP
Kyowa Hakko Kirin Co., Ltd.
Norton Gerard P.
The Rockefeller University
LandOfFree
In vivo expanded NKT cells and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with In vivo expanded NKT cells and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vivo expanded NKT cells and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4207506